TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the successful completion of the research results and filing of a U.S. provisional patent application with The United States…


Previous articleAion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells
Next articleChampignon Brands Announces Revocation of Cease Trade Orders